Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance.
The occurrence of endocrine cells in 350 cases of colorectal adenocarcinoma was studied by immunohistochemistry for chromogranin A (CGA). The hormone profile of endocrine tumor cells, the correlation between endocrine differentiation and presence of other colorectal epithelial-cell lineages and the prognostic relevance of endocrine differentiation in colorectal cancer were investigated. CGA-positive tumor cells were found in 30% of cases, 21% showing moderate positivity and 9.0% extensive positivity. Of CGA-positive tumors, 70% additionally produced neurohormones, mainly indigenous to normal colorectal epithelium: 55% showed immunoreactivity for glucagon-like substances, 20% for serotonin and 10% for somatostatin, PYY and HCG. No immunoreactivity was found for various neurohormones not normally produced by colorectal endocrine cells. CGA-positive tumors tended to be more aggressive than CGA-negative tumors. Especially, tumors with extensive CGA positivity showed shorter survival, which was most apparent within Dukes' stage C. In multivariate analysis, extensive CGA positivity was an independent indicator of poor prognosis. CGA immunoreactivity significantly correlated with mucin production, but not with expression of secretory component (SC), a columnar-cell marker. Mucin production significantly correlated with SC expression. Tumors positive for CGA but not for mucin and/or SC showed the worst prognosis. SC expression was a relatively favorable feature, and mucin-producing tumors showed intermediate behavior.
de Bruïne
A P
AP
Department of Pathology, University Hospital Maastricht, The Netherlands.
Wiggers
T
T
Beek
C
C
Volovics
A
A
von Meyenfeldt
M
M
Arends
J W
JW
Bosman
F T
FT
D000230:Adenocarcinoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis*; D003110:Colonic Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D003593:Cytoplasm / Q000737:chemistry; D004702:Endocrine Glands / Q000737:chemistry / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D053771:Glicentin; D005934:Glucagon / Q000032:analysis; D004763:Glucagon-Like Peptides; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000032:analysis; D011379:Prognosis; D011446:Prospective Studies; D011498:Protein Precursors / Q000032:analysis; D012004:Rectal Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D012701:Serotonin / Q000032:analysis; D013004:Somatostatin / Q000032:analysis; D016019:Survival Analysis
D053379:Chromogranin A; D002864:Chromogranins; D010446:Peptide Fragments; D011498:Protein Precursors; D012701:Serotonin; D013004:Somatostatin; D004763:Glucagon-Like Peptides; D053771:Glicentin; D005934:Glucagon